2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era




Although the multifactorial causes of multiple sclerosis (MS) are not known, an improved understanding of the neuroimmunologic pathogenesis has led to the development of a wide variety of disease-modifying treatments (DMTs). While there is no cure for MS, these treatments can reduce disease activity and delay MS progression and disability.

However, having more DMT options than ever, and more still in clinical development, further complicates treating an already complex condition. With a wide variety of mechanisms of action (MOAs), selecting the optimal DMT is a formidable challenge with the opportunity to improve short-and long-term outcomes. Yet, using a treatment that is unsuitable to the patient’s individual disease activity, prognosis, and preferences is likely to lead to intolerable adverse events (AEs) and nonadherence. Given an MS patient’s immunosuppressed status and increased risk of infection. Adherence issues are further compounded during the pandemic as a result of stay-at-home orders.

Personalized treatment incorporates patient preferences for selecting, starting, switching, and stopping therapies as the patient’s circumstances change, as the disease progresses, and as the patient ages. Parsing the therapeutic alternatives can yield the most benefit when an interdisciplinary shared decision-making (SDM) approach is used. MS is a therapeutic area that is rapidly evolving and neurology clinicians need to remain updated on emerging therapies.

Through this initiative, participants will gain the knowledge and competence to develop early, aggressive plans that balance the benefits and risks of MS treatment options in order to optimize patient management through SDM.


Aaron Boster, MD
Founder and President
The Boster Center for Multiple Sclerosis
Columbus, Ohio


Patricia K. Coyle, MD
Vice Chair, Clinical Affairs
Director, MS Comprehensive Care Center
Department of Neurology
Stony Brook University
Stony Brook, New York


Release date: April 30, 2021
Expiration date: April 30, 2022
Estimated time to complete activity: 1.5 hour(s)



This program is intended for MS specialists, neurologists, internists, nurse practitioners, and physician assistants who are involved in the care of patients with MS.


Upon completion of this educational activity, participants should be able to:

  • Recognize the importance of early diagnosis and treatment in reducing disability progression among patients with MS
  • Personalize treatment selection when starting, switching, or stopping a pharmacologic treatment based on efficacy, safety, and patient preference
  • Evaluate the latest data on the efficacy, safety, and dosing/administration of currently approved DMTs to develop optimal individualized treatment strategies for patients with MS
  • Evaluate potential benefits of emerging therapies in delaying disability, slowing disease progression, and improving long-term outcomes in MS
  • Identify up-to-date recommendations for patients with MS during COVID-19 era, including registries and treatment considerations

There are no fees for participating and receiving CME credit for this activity. During the period of April 30, 2021 through April 30, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Accreditation Statement
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or information@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Aaron Boster, MD
Consulting Fees: EMD Serono, Genentech, Genzyme​, Novartis
Speakers’ Bureaus: EMD Serono, Genentech, Genzyme​

Patricia K. Coyle, MD
Consulting Fees: Accordant, Biogen, Bristol-Myers Squibb, Celgene, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers’ Bureaus: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona LLC, Genetech/Roche, MedDay, National Institute of Neurological Disorders and Stroke, Novartis

The Integrity Continuing Education, Inc. planners/managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Provided by Integrity Continuing Education, Inc.


Supported by independent educational grants from Biogen and EMD Serono, Inc.


Continue to Pretest